Microbot Medical ( NASDAQ: $MBOT) has signed a partnership with Lovell Government Services to expand access to its LIBERTY endovascular robotic system across major U.S….
Every June 16, the world marks International Biotechnology Day, recognizing the scientific breakthroughs that have reshaped medicine, agriculture, environmental science, and industry. The date traces…
The FDA has cleared Dexcom’s (NASDAQ: DXCM) Stelo Glucose Biosensor System as the first over‑the‑counter continuous glucose monitor (CGM) that children can use, extending earlier…
June 10, 2026
Lexaria Advances Next-Generation GLP-1 Research With Completion of Dosing in New Animal Study
Lexaria Bioscience Corp. (NASDAQ: LEXX) has completed dosing in its 2026 Animal Study #2 (GLP-1-A26-2), which is evaluating orally delivered formulations of two next-generation GLP-1…
RedHill Biopharma’s (NASDAQ: RDHL) oral drug candidate opaganib has received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration for the treatment…
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is expanding beyond its traditional biotech focus with a small but strategic move into medical devices, agreeing to acquire Israeli…
Tango Therapeutics, Inc. (NASDAQ: TNGX) is breaking out sharply today, with shares jumping about 45% to 29.38 from a prior close of 20.22. The stock…
June 05, 2026
BioCardia’s Stock Surges on Clearer FDA Trial Path
BioCardia Inc. (NASDAQ: BCDA) is surging after the company said U.S. regulators have confirmed the trial pathway for its lead heart‑failure program. This latest move…
June 04, 2026
FDA Signals a Renewed Posture Toward Rare Disease
A recent meeting between acting FDA Commissioner Kyle Diamantas and senior executives from fifteen rare disease nonprofits offers a useful read on where the agency…
Iovance Biotherapeutics (NASDAQ: IOVA) is getting a welcome boost after Australia signed off on its flagship melanoma therapy, adding another pillar to the company’s global…
TG Therapeutics (NASDAQ: TGTX) is trading higher after fresh clinical data supported a more convenient, under‑the‑skin version of its multiple sclerosis therapy Briumvi (ublituximab‑xiiy), reinforcing…
June 03, 2026
CytomX Therapeutics, Inc. Partners with Regeneron for 4 Billion Dollar Oncology Initiative
CytomX Therapeutics, Inc. (NASDAQ: CTMX) officially announced a major expansion of its strategic research collaboration and licensing agreement with Regeneron Pharmaceuticals, Inc. on June 3,…